Search
for
Sort by
Research 241–270 of 1000+
- Factors Associated with Severity of Alopecia Areata
- Treatment of severe alopecia areata with baricitinib
- Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims
- Acquired trichomegaly of the eyelashes and hypertrichosis induced by bimatoprost
- Tinea capitis mimicking cicatricial alopecia: What host and dermatophyte factors lead to this unusual clinical presentation?
- Secondary cicatricial and other permanent alopecias
- Topical use of systemic drugs in dermatology: A comprehensive review
- Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity
- Spectrum of mucocutaneous manifestations in human immunodeficiency virus-infected patients and its correlation with CD4 lymphocyte count
- Urticaria, Drug Hypersensitivity Rashes, Nodules and Tumors, and Atrophic Diseases
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- A REVIEW ON PHYTOPHARMACOLOGICAL SIGNIFICANCE OF ECLIPTA ALBA
- The Skin and Subcutaneous Tissues
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Clinical and Therapeutic evaluation of Canine demodicosis
- Mechanistic study of Erianin in alopecia areata
- Successful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab
- Ritlecitinib in severe alopecia areata: a profile of its use
- Improvement of Hair Growth in Mouse Skin by Application of Consciousness Energy Treated Test Item
- Subject Index
- British Society for Dermatopathology
- Recognition and management of <i>Staphylococcus aureus</i> toxin‐mediated disease
- Methotrexate in dermatology
- Oral Manifestations of Hematologic and Nutritional Diseases
- Hair loss in elderly women
- Dermatological manifestations associated with COVID‐19: A comprehensive review of the current knowledge
- CUTANEOUS SIDE-EFFECTS OF BETA-ADRENERGIC BLOCKERS
- Cutaneous manifestations of metabolic diseases: uncommon presentations
- Skin manifestations of chronic kidney disease
- Dermatologic Reactions to Targeted Therapy